Amwell (NYSE: AMWL) reported Q3 EPS of ($2.87), $2.68 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $61.05 million versus the consensus estimate of $64.55 million.

For earnings history and earnings-related data on Amwell (AMWL) click here.